CRUK-MEDI Alliance Laboratory

CRUK-MEDI Alliance Laboratory

The Cancer Research UK–MedImmune Alliance Laboratory helps you translate your novel research into therapeutic and diagnostic antibodies.

The laboratory brings together CRUK’s cancer biology expertise with the world-class antibody engineering technology of MedImmune, the global biologics research and development arm of AstraZeneca.

Scientists from both organisations work side by side in the joint laboratory in Cambridge, sharing knowledge and expertise to accelerate the discovery and development of novel biologics to treat and diagnose cancer.

Our mission

  • To maximise cancer patient benefit
  • To run a collaborative research laboratory
  • To actively engage the oncology research community
  • To partner closely with investigators

We invite researchers to apply to access this unique laboratory and expertise, to develop novel therapeutic and diagnostic antibodies. We are seeking promising new insights from novel biology through to well-validated targets, to underpin our discovery activities.

The laboratory provides researchers with a fantastic opportunity to:

  • turn your concept into a drug and bring benefit to cancer patients
  • secure resources and funding to conduct focused research on your target
  • be a key member of a multidisciplinary drug discovery team
  • gain insight and understanding of leading biotherapeutic drug discovery technologies
  • author on both research articles and patents

To find out more about the laboratory, take a look at our press release and blog post.

Governance

CRUK Medimmune Alliance Lab teamThe lab is governed by a Joint Steering Committee comprising representatives from both CRUK and MedImmune.

From left to right: Maria Groves (Head of laboratory), Jane Osbourn (MedImmune), Keith Blundy (CRT), Iain Foulkes (CRUK), Nigel Blackburn (CRUK), Tristan Vaughan (MedImmune) and Sarah Holt (Deputy head of laboratory) at a recent meeting of the Joint Steering Committee.

 

Contact us

If you have any further questions about the laboratory or whether your project is eligible, please contact the team at AllianceLab@cancer.org.uk or speak to your CRT Business Manager.

Meet the team

Staff from the Lab will be exhibiting at the following events and conferences:

NCRI Conference, Liverpool, UK
6–9 November 2016

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Munich, Germany
29 November–2 December 2016

Email us to arrange a meeting at one of these events.

Apply to access the laboratory

To access the laboratory you must complete a Target Notice Form.

Download a Target Notice Form

Where next for cancer immunotherapy?

Where next for cancer immunotherapy?

We're driving discovery research in immuno-oncology which is leading to novel and exciting immunotherapeutic possibilities.

Celebrating the CRUK-MEDI Alliance Laboratory

Celebrating UK Bioscience - Cancer case study

As part of a series celebrating UK expertise in drug discovery and development, the UK BioIndustry Association visited the CRUK-MEDI Alliance Laboratory.

Share this page